Gan & Lee Pharmaceuticals. (SHA:603087)
China · Delayed Price · Currency is CNY 67.46
-0.85 (-1.24%)
Oct 28, 2026, 10:55 AM CST
SHA:603087 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,730 | 2,088 | 903.03 | 2,443 | 2,890 | 3,306 |
Short-Term Investments | - | 324.46 | - | - | 201.36 | 276.44 |
Trading Asset Securities | 2,529 | 1,401 | 1,500 | 2,410 | 1,636 | 1,624 |
Cash & Short-Term Investments | 4,259 | 3,814 | 2,404 | 4,853 | 4,728 | 5,206 |
Cash Growth | 34.52% | 58.68% | -50.48% | 2.66% | -9.20% | 14.24% |
Accounts Receivable | 936.59 | 599.87 | 251.81 | 383.74 | 189.57 | 934.66 |
Other Receivables | 7.3 | -0.16 | 8.29 | 1.63 | 0.99 | 0.16 |
Receivables | 943.89 | 599.71 | 260.1 | 385.37 | 190.55 | 934.82 |
Inventory | 1,192 | 1,009 | 1,053 | 860.51 | 648.65 | 651.33 |
Other Current Assets | 315.78 | 61.78 | 74.33 | 76.73 | 97.36 | 77.95 |
Total Current Assets | 6,711 | 5,484 | 3,791 | 6,176 | 5,664 | 6,870 |
Property, Plant & Equipment | 3,699 | 3,577 | 3,882 | 3,886 | 3,661 | 2,595 |
Long-Term Investments | 303.83 | 1,346 | 2,897 | 304.66 | 30 | 201.36 |
Other Intangible Assets | 606.68 | 265.11 | 273.06 | 278.08 | 293.48 | 295.99 |
Long-Term Deferred Tax Assets | 163.55 | 213.67 | 206.94 | 168.95 | 138.25 | 30.8 |
Long-Term Deferred Charges | 1,784 | 1,611 | 924.91 | 821.97 | 743.19 | 588.87 |
Other Long-Term Assets | 410.09 | 129.05 | 68.13 | 79.99 | 76.51 | 270.33 |
Total Assets | 13,679 | 12,627 | 12,043 | 11,715 | 10,607 | 10,853 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 249.08 | 126.21 | 115.61 | 94.82 | 36.52 | 26.15 |
Accrued Expenses | 188.4 | 295.26 | 196.96 | 192.54 | 190 | 173.04 |
Current Portion of Leases | - | 1.2 | 1.33 | 2.18 | 5.69 | 5.07 |
Current Income Taxes Payable | 107.13 | 14.53 | 1.49 | 1.42 | 1.35 | 106.32 |
Current Unearned Revenue | 32.79 | 67.88 | 63.25 | 52.99 | 68.13 | 36.56 |
Other Current Liabilities | 661.76 | 310.69 | 422.48 | 429.49 | 511.36 | 138.39 |
Total Current Liabilities | 1,244 | 815.79 | 801.13 | 773.45 | 813.04 | 485.53 |
Long-Term Debt | 228.08 | - | - | - | - | - |
Long-Term Leases | 1.65 | 2.54 | 3.31 | 5.45 | 8.33 | 12.17 |
Long-Term Unearned Revenue | 211.33 | 170.75 | 168.92 | 179.63 | 187.63 | 141.98 |
Long-Term Deferred Tax Liabilities | 13.55 | - | 12.11 | - | - | 36.15 |
Other Long-Term Liabilities | 2.68 | 9.5 | 2.97 | 14 | 12.27 | 10.2 |
Total Liabilities | 1,702 | 998.57 | 988.45 | 972.52 | 1,021 | 686.02 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 597.43 | 597.3 | 601.07 | 594.16 | 565.65 | 561.54 |
Additional Paid-In Capital | 3,573 | 3,534 | 3,591 | 3,351 | 2,563 | 2,476 |
Retained Earnings | 7,867 | 7,606 | 7,059 | 6,865 | 6,525 | 7,133 |
Treasury Stock | -61.62 | -111.17 | -200.85 | -71.36 | -71.36 | - |
Comprehensive Income & Other | 1.24 | 3.06 | 4.04 | 3.82 | 3.44 | -3.44 |
Total Common Equity | 11,977 | 11,628 | 11,054 | 10,743 | 9,586 | 10,167 |
Minority Interest | - | - | - | 0 | -0.16 | -0.16 |
Shareholders' Equity | 11,977 | 11,628 | 11,054 | 10,743 | 9,586 | 10,167 |
Total Liabilities & Equity | 13,679 | 12,627 | 12,043 | 11,715 | 10,607 | 10,853 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 235.02 | 3.74 | 4.64 | 7.62 | 14.01 | 17.24 |
Net Cash (Debt) | 4,024 | 3,810 | 2,399 | 4,846 | 4,714 | 5,189 |
Net Cash Growth | 27.20% | 58.83% | -50.49% | 2.80% | -9.16% | 13.86% |
Net Cash Per Share | 6.80 | 6.43 | 4.06 | 8.55 | 8.37 | 9.25 |
Filing Date Shares Outstanding | 591.31 | 591.12 | 598.96 | 590.05 | 561.54 | 561.54 |
Total Common Shares Outstanding | 591.31 | 591.12 | 598.96 | 590.05 | 561.54 | 561.54 |
Working Capital | 5,467 | 4,668 | 2,990 | 5,402 | 4,851 | 6,385 |
Book Value Per Share | 20.26 | 19.67 | 18.46 | 18.21 | 17.07 | 18.11 |
Tangible Book Value | 11,370 | 11,363 | 10,781 | 10,464 | 9,292 | 9,871 |
Tangible Book Value Per Share | 19.23 | 19.22 | 18.00 | 17.73 | 16.55 | 17.58 |
Buildings | - | 2,173 | 2,137 | 1,344 | 1,165 | 1,046 |
Machinery | - | 2,286 | 1,601 | 1,443 | 1,237 | 1,263 |
Construction In Progress | - | 393.47 | 1,262 | 2,007 | 2,003 | 874.91 |